Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20791367 | 0.81 | KDM1A (0.37) | P2RX3P2RX2KDM1AALDH1A1GAA | |
| SCHEMBL20791368 | 0.81 | KDM1A (0.37) | P2RX3P2RX2KDM1AALDH1A1GAA | |
| SCHEMBL12190518 | 0.77 | P2RX3 (0.48) | P2RX3P2RX2KDM1AGAAHTT | |
| SCHEMBL16861757 | 0.72 | PDE2A (0.38) | ALDH1A1HTTHTR2AHTR2CHTR2B | |
| SCHEMBL2937347 | 0.72 | LMNA (0.46) | P2RX3P2RX2KDM1AHTTHTR2A | |
| SCHEMBL23666032 | 0.70 | GAA (0.48) | P2RX3P2RX2ALDH1A1GAAHPGD | |
| SCHEMBL5183952 | 0.69 | MGAM (0.39) | P2RX3P2RX2GAAHTTSTING1 | |
| SCHEMBL28053612 | 0.69 | ROCK2 (0.44) | — | |
| SCHEMBL28053615 | 0.69 | ROCK2 (0.44) | — | |
| SCHEMBL17549452 | 0.68 | KDM4E (0.48) | ALDH1A1HPGDHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | P2RX3 1583/4885P2RX2 1345/4885KDM1A 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.